• Home
  • News
  • Fortune 500
    • Fortune Global 500
    • Fortune 500 Europe
    • Fortune China 500
    • Fortune SEA 500
    • Great Place to Work
  • Tech
    • AI
    • Innovation
    • Cybersecurity
  • Finance
    • Personal Finance
    • Real Estate
    • Economy
    • Investing
    • Banking
    • Crypto
  • Leadership
    • Success
    • Future of Work
    • Workplace Culture
    • C-Suite
    • CEO Initiative
  • Lifestyle
    • Arts & Entertainment
    • Travel & Leisure
    • Health
    • Well
    • Education
  • Rankings
    • Analytics
  • Multimedia
    • Live Media
    • Magazine
    • Newsletters
    • Video
    • Podcasts
  • Home
  • News
  • FORTUNE 500
    • FORTUNE 500
    • FORTUNE SEA 500
    • Fortune 500 Europe
    • Fortune Global 500
    • Fortune China 500
    • Great Place to Work
  • Tech
    • Tech
    • AI
    • Innovation
    • Cybersecurity
  • Finance
    • Finance
    • Personal Finance
    • Real Estate
    • Economy
    • Banking
    • Investing
    • Crypto
  • Leadership
    • Leadership
    • Success
    • Future of Work
    • Workplace Culture
    • C-Suite
    • CEO Initiative
  • Lifestyle
    • Lifestyle
    • Arts & Entertainment
    • Travel & Leisure
    • Health
    • Well
    • Education
  • Rankings
    • Rankings
    • Analytics
  • Multimedia
    • Multimedia
    • Live Media
    • Magazine
    • Newsletters
    • Video
    • Podcasts
  • Asia
  • Europe
  • Analytics

Bill Novelli

  • An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. Patients, doctors and pharmacists across the US are struggling to get their hands on Eli Lilly & Co.’s powerful new obesity drug Zepbound, as demand for the weight-loss shot soars. Photographer: Shelby Knowles/Bloomberg via Getty ImagesCommentary

    Here’s the real reason Ozempic-like weight-loss drugs are so popular

    By Bill Novelli
  • LONDON, UNITED KINGDOM – 2023/05/13: A protester holds a placard during the Truth Be Told Demo while marching to Parliament Square in London. In June 2023, the government plans to expand the age group of those eligible to get vaccinated with Covid-19 vaccines to 6-month-olds. Anti-covid vaccine demonstrators were protesting against this plan pointing to the possible risks posed by Covid vaccines. Some relatives of those who allegedly died from the Covid-19 vaccines also joined the protest to seek justice for their loved ones. Currently, the government only allows 5-year-olds and above to get the Covid-19 vaccine. (Photo by Loredana Sangiuliano/SOPA Images/LightRocket via Getty Images)Commentary

    ‘An age of manufactured mistrust’: Here’s what rampant disinformation means for health, climate, and democracy

    By Bill Novelli
  • The mid adult woman helps her senior adult friend carefully enter her home.Commentary

    Millennials and Gen Xers might be the unluckiest caregivers in history. Here’s how their crisis is affecting every workplace

    By Bill Novelli
  • Calm business man standing above high-rise rooftop overlooking the city view at sunset.Commentary

    ESG is under attack–but Gen Zers and millennials are still looking for purpose and a paycheck

    By Bill Novelli
  • WASHINGTON, DC – MAY 10: A mobile billboard calling out House Oversight Committee Republicans rolls past the U.S. Capitol on May 10, 2023 in Washington, DC. (Photo by Jemal Countess/Getty Images for Congressional Integrity Project)Commentary

    Climate change is the next frontier of America’s culture wars. Corporations are still doing the right thing–and hoping no one notices

    By Bill Novelli
  • JERSEY CITY, NJ – MAY 25: A seagull flies in front of the skyline of Brooklyn, the Brooklyn Tower and the Statue of Liberty as the sun rises in New York City on May 25, 2023, as seen from Jersey City, New Jersey.  (Photo by Gary Hershorn/Getty Images)Commentary

    America can’t fulfill its purpose if we backslide on diversity, equity, and inclusion

    By Bill Novelli
    Rankings
    • 100 Best Companies
    • Fortune 500
    • Global 500
    • Fortune 500 Europe
    • Most Powerful Women
    • Future 50
    • World’s Most Admired Companies
    • See All Rankings
    Sections
    • Finance
    • Leadership
    • Success
    • Tech
    • Asia
    • Europe
    • Environment
    • Fortune Crypto
    • Health
    • Retail
    • Lifestyle
    • Politics
    • Newsletters
    • Magazine
    • Features
    • Commentary
    • MPW
    • CEO Initiative
    • Conferences
    • Personal Finance
    • Education
    Customer Support
    • Frequently Asked Questions
    • Customer Service Portal
    • Privacy Policy
    • Terms of Use
    • Single Issues for Purchase
    • International Print
    Commercial Services
    • Advertising
    • Fortune Brand Studio
    • Fortune Analytics
    • Fortune Conferences
    • Business Development
    About Us
    • About Us
    • Editorial Calendar
    • Press Center
    • Work at Fortune
    • Diversity and Inclusion
    • Terms and Conditions
    • Site Map

    © 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
    FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.